Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2017-08-08 |
Radius Health (USA - MA) |
$300 million |
private placement |
|
Bone diseases - Cancer - Oncology - Endocronological diseases |
Private placement |
2017-08-07 |
Cuorips (Japan) |
|
investment |
Daiichi Sankyo (Japan) |
|
Fundraising |
2017-08-04 |
Lonza (Switzerland) |
€ 700 million and $ 200 million |
private placement |
|
Technology - Services |
Company acquisition |
2017-08-01 |
Homology Medicines (USA - MA) |
$83.5 million |
series B financing round |
5AM Ventures (USA - CA) Alexandria Venture Investments (USA - MA) ARCH Venture Partners (USA - IL) Deerfield Management (USA - NY) Fidelity Management and Research Company (US - MA) HBM Healthcare Investments (Switzerland) Maverick Ventures USA - CA) Novartis (Switzerland) Rock Springs Capital (USA - MD) Vida Ventures (Canada) Vivo Capital (USA - CA) |
Rare diseases - Genetic diseases |
Series B financing round |
2017-07-31 |
Neovacs (France) |
€6.0 million |
private placement |
undisclosed U.S. institutional investors |
Autoimmune diseases |
Private placement |
2017-07-28 |
Iteos Therapeutics (Belgium) |
€ 7.5 million |
grant |
Walloon Region (Belgium) |
Cancer - Oncology |
Grant |
2017-07-26 |
Quantum Genomics (France) |
€ 8.2 Million |
capital increase |
|
Cardiovascular diseases |
Capital increase |
2017-07-25 |
Antabio (France) |
up to $8.9 million |
grant |
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) |
Infectious diseases |
Grant |
2017-07-25 |
Debiopharm (Switzerland) |
up to $ 4 million |
grant |
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) |
Infectious diseases |
Grant |
2017-07-25 |
Achaogen (USA - CA) |
up to $ 11.5 million |
grant |
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) |
Infectious diseases |
Grant |
2017-07-25 |
Bugworks Research Inidia (India) |
up to $ 6.2 million |
grant |
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) |
Infectious diseases |
Grant |
2017-07-25 |
Eligochem (UK) |
up to $ 4.8 million |
grant |
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) |
Infectious diseases |
Grant |
2017-07-25 |
Iterum Therapeutics (Ireland) |
up to $ 1.5 million |
grant |
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) |
Infectious diseases |
Grant |
2017-07-25 |
VenatoRx Pharmaceuticals (USA - PA) |
up to $ 9.4 million |
grant |
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) |
Infectious diseases |
Grant |
2017-07-24 |
Intralytix (USA - MA) |
$17.5 million |
private placement |
Lesaffre (France) |
Infectious diseases |
Private placement |
2017-07-19 |
Ose Immunotherapeutics (France) |
€9.2 million |
grant |
Bpifrance (France) |
Cancer - Oncology |
Grant |
2017-07-19 |
Akcea Therapeutics (USA - MA) |
$193.8 million |
IPO - private placement |
|
Cardiovascular diseases - Metabolic diseases - Rare diseases |
IPO |
2017-07-18 |
Eurofins Scientific (Luxembourg) |
€ 65 million |
fundraising |
|
Technology - Services |
Fundraising |
2017-07-18 |
Neurovive Pharmaceutical (Sweden) |
SEK 9 million (€ 0.94 million) |
private placement |
Esousa Holdings (USA - NY) |
Rare diseases - Genetic diseases - Liver diseases - Hepatic diseases |
Private placement |
2017-07-18 |
Amicus Therapeutics (USA - NJ) |
$258.8 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |